Open AccessA systematic analysis of orphan cyclins reveals CNTD2 as a new oncogenic driver in lung cancer
Author(s) -
Laura Gasa,
Abril Sánchez-Botet,
Eva Quandt,
Sara Hernández-Ortega,
Javier Jiménez,
Miquel Àngel Carrasco-García,
Sara Simonetti,
Stephen J. Kron,
Mariana P.C. Ribeiro,
Ernest Nadal,
Alberto Villanueva,
Josep Clotet
Publication year - 2017
Publication title -
scientific reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.24
H-Index - 213
ISSN - 2045-2322
DOI - 10.1038/s41598-017-10770-8
Subject(s) - lung cancer , cancer research , cancer , cyclin , biology , cyclin d1 , cell growth , cell cycle , carcinogenesis , biomarker , medicine , pathology , genetics
As lung cancer has increased to the most common cause of cancer death worldwide, prognostic biomarkers and effective targeted treatments remain lacking despite advances based on patients’ stratification. Multiple core cyclins, best known as drivers of cell proliferation, are commonly deregulated in lung cancer where they may serve as oncogenes. The recent expansion of the cyclin family raises the question whether new members might play oncogenic roles as well. Here, we investigated the protein levels of eight atypical cyclins in lung cancer cell lines and formalin-fixed and paraffin-embedded (FFPE) human tumors, as well as their functional role in lung cancer cells. Of the new cyclins evaluated, CNTD2 was significantly overexpressed in lung cancer compared to adjacent normal tissue, and exhibited a predominant nuclear location. CNTD2 overexpression increased lung cancer cell viability, Ki-67 intensity and clonogenicity and promoted lung cancer cell migration. Accordingly, CNTD2 enhanced tumor growth in vivo on A549 xenograft models. Finally, the analysis of gene expression data revealed a high correlation between elevated levels of CNTD2 and decreased overall survival in lung cancer patients. Our results reveal CNTD2 as a new oncogenic driver in lung cancer, suggesting value as a prognostic biomarker and therapeutic target in this disease.